Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
ID6130: Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over
ID6170: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A
ID5123: Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
ID3982: Relugolix–estradiol–norethisterone for treating symptoms of endometriosis
ID6405: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
ID5088: Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria
ID4042: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia
ID6298: Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
ID6197: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion
ID6187: Relugolix for treating hormone-sensitive prostate cancer
ID4025: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
ID5104: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over
ID4038: Therapeutics for people with COVID-19
ID1334: Glasdegib with chemotherapy for untreated acute myeloid leukaemia
ID2710: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375)
ID1596: Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly
ID1625: Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma
ID1631: Risdiplam for treating spinal muscular atrophy in children and adults
ID1564: Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
ID1609: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
ID1604: Esketamine for treating major depressive disorder in adults at imminent risk for suicide
ID1589: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
ID945: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
ID3787: Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis
ID1553: Cenobamate for focal onset seizures in epilepsy
ID3802: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
ID3734: Tralokinumab for treating moderate to severe atopic dermatitis
ID2722: Belimumab for treating lupus nephritis
ID1624: Berotralstat for preventing acute attacks of hereditary angioedema
ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE IDs
NICE IDs
11/10/2021
ID1604: Esketamine for treating major depressive disorder in adults at imminent risk for suicide
11/10/2021
ID1589: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
11/10/2021
ID945: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
11/10/2021
ID3787: Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis
11/10/2021
ID1553: Cenobamate for focal onset seizures in epilepsy
11/10/2021
ID3802: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
11/10/2021
ID3734: Tralokinumab for treating moderate to severe atopic dermatitis
11/10/2021
ID2722: Belimumab for treating lupus nephritis
11/10/2021
ID1624: Berotralstat for preventing acute attacks of hereditary angioedema
11/10/2021
ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction
11/10/2021
ID1090: Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies
11/10/2021
ID3892: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
11/10/2021
ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction
11/10/2021
ID1083: Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia
11/10/2021
ID1557: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
11/10/2021
ID2727: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
11/10/2021
ID1087: Fostamatinib for treating persistent or chronic immune thrombocytopenia
11/10/2021
ID1393: Ponesimod for treating relapsing multiple sclerosis
11/10/2021
ID1573: Midostaurin for treating advanced systemic mastocytosis
11/10/2021
ID3826: Empagliflozin for treating chronic heart failure with reduced ejection fraction
1
2
3
4
5
6
7
Follow AWTTC:
